Lataa...
Advances in immunotherapy for melanoma
In recent years, the introduction and Federal Drug Administration approval of immune checkpoint inhibitor antibodies has dramatically improved the clinical outcomes for patients with advanced melanoma. These antagonist monoclonal antibodies are capable of unleashing dormant or exhausted antitumor im...
Tallennettuna:
| Julkaisussa: | BMC Med |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4744430/ https://ncbi.nlm.nih.gov/pubmed/26850630 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-016-0571-0 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|